MXPA01008626A - Inhibidor novedoso de muerte programada de celula. - Google Patents

Inhibidor novedoso de muerte programada de celula.

Info

Publication number
MXPA01008626A
MXPA01008626A MXPA01008626A MXPA01008626A MXPA01008626A MX PA01008626 A MXPA01008626 A MX PA01008626A MX PA01008626 A MXPA01008626 A MX PA01008626A MX PA01008626 A MXPA01008626 A MX PA01008626A MX PA01008626 A MXPA01008626 A MX PA01008626A
Authority
MX
Mexico
Prior art keywords
aven
amino acid
sequence
vector
dna
Prior art date
Application number
MXPA01008626A
Other languages
English (en)
Spanish (es)
Inventor
J Marie Hardwick
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of MXPA01008626A publication Critical patent/MXPA01008626A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747Apoptosis related proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
MXPA01008626A 1999-02-26 2000-02-24 Inhibidor novedoso de muerte programada de celula. MXPA01008626A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12210499P 1999-02-26 1999-02-26
PCT/US2000/004613 WO2000050453A1 (en) 1999-02-26 2000-02-24 A novel inhibitor of programmed cell death

Publications (1)

Publication Number Publication Date
MXPA01008626A true MXPA01008626A (es) 2002-04-24

Family

ID=22400634

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01008626A MXPA01008626A (es) 1999-02-26 2000-02-24 Inhibidor novedoso de muerte programada de celula.

Country Status (7)

Country Link
US (1) US6570002B1 (enExample)
EP (1) EP1161444A4 (enExample)
JP (1) JP2002540769A (enExample)
AU (1) AU760466B2 (enExample)
CA (1) CA2363621A1 (enExample)
MX (1) MXPA01008626A (enExample)
WO (1) WO2000050453A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100111928A1 (en) * 1997-05-23 2010-05-06 A & G Pharmaceutical, Inc. Methods and kits for diagnosis tumorgenicity
US20030215445A1 (en) 1997-05-23 2003-11-20 Ginette Serrero Methods and compositions for inhibiting the growth of hematopoietic malignant cells
AU2002315534B2 (en) * 2001-07-10 2008-05-22 Biogen Idec Inc. Inhibition of apoptosis process and improvement of cell performance
US7411045B2 (en) * 2002-11-19 2008-08-12 A&G Pharmaceutical, Inc. Autocrine growth factor receptor antibodies and methods
AU2003901010A0 (en) * 2003-03-06 2003-03-20 Flinders Technologies Pty Ltd Apoptosis regulator
EP1644038A2 (en) * 2003-06-23 2006-04-12 A & G Pharmaceuticals, Inc. Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis
WO2005011590A2 (en) * 2003-08-01 2005-02-10 A & G Pharmaceutical, Inc. Compositions and methods for restoring sensitivity to treatment with her2 antagonists
ES2358267T3 (es) 2004-03-15 2011-05-09 Sunesis Pharmaceuticals, Inc. Composición farmacéutica que comprende sns-595 y sus usos.
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
EP2354138A1 (en) 2006-06-12 2011-08-10 Sunesis Pharmaceuticals, Inc. Compounds and compositions for treatment of cancer
SI2049109T1 (sl) * 2006-08-02 2016-04-29 Sunesis Pharmaceuticals, Inc. Kombinirana uporaba(+)-1,4-dihidro-7-((3s,4s)-3-metoksi-4-(metilamino)- 1-pirolidinil)-4-okso-1-(2-tiazolil)-1,8-naftiridin-3-karboksilne kisline in citarabina (ara-c) za zdravljenje levkemije
EP2214662B1 (en) * 2007-10-22 2016-07-13 Sunesis Pharmaceuticals, Inc. (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination with gemcitabine for use in treating cancer
AU2016306694B2 (en) 2015-08-12 2021-03-11 Memorial Sloan-Kettering Cancer Center Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US5646008A (en) 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods
US5622852A (en) 1994-10-31 1997-04-22 Washington University Bcl-x/Bcl-2 associated cell death regulator
US5539094A (en) 1993-11-12 1996-07-23 La Jolla Cancer Research Foundation DNA encoding Bcl-2-associated proteins
FI962247A7 (fi) 1993-11-30 1996-07-22 Lxr Biotechnology Inc Uudet apoptoosia muuntavat proteiinit, niitä koodaava DNA ja näiden kä yttömenetelmät
US5858678A (en) 1994-08-02 1999-01-12 St. Louis University Apoptosis-regulating proteins
US5858715A (en) 1997-01-29 1999-01-12 Incyte Pharmaceuticals, Inc. Human apoptosis-associated protein

Also Published As

Publication number Publication date
AU3374000A (en) 2000-09-14
EP1161444A4 (en) 2005-11-02
CA2363621A1 (en) 2000-08-31
JP2002540769A (ja) 2002-12-03
AU760466B2 (en) 2003-05-15
EP1161444A1 (en) 2001-12-12
US6570002B1 (en) 2003-05-27
WO2000050453A1 (en) 2000-08-31

Similar Documents

Publication Publication Date Title
CA2220753C (en) Novel peptides and compositions which modulate apoptosis
JP2002521055A (ja) 98個のヒト分泌タンパク質
JP2009131263A (ja) 50個のヒト分泌タンパク質
US6570002B1 (en) Inhibitor of programmed cell death
US6545128B1 (en) Anti-bax inhibitor protein antibodies
US5763220A (en) Human apoptosis-related calcium-binding protein
JP2001517943A (ja) ヒト膵炎関連タンパク質、pap−2
US5858715A (en) Human apoptosis-associated protein
JP4314386B2 (ja) Bcl−2調節因子(BMF)配列及びアポトーシスの調節におけるそれらの使用
JP2003508011A (ja) ヒトfez1遺伝子である新規ガン抑制遺伝子に関する組成物、キットおよび方法
US6773911B1 (en) Apoptosis-inducing factor
JP2001515352A (ja) タンパク質キナーゼcインヒビタ様タンパク質(ipkc−2)
AU736210B2 (en) Brca1 compositions and methods for the diagnosis and treatment of breast cancer
KR20010085816A (ko) 면역 관련 질환 치료용 조성물 및 치료 방법
US6307021B1 (en) Human apoptosis regulator
CA2352467C (en) Apoptosis-inducing factor
WO1998001460A9 (en) Brca1 compositions and methods for the diagnosis and treatment of breast cancer
JP2000517175A (ja) ヒトdbi/acbp様タンパク質
CN100443501C (zh) 人骨髓基质细胞来源的线粒体转运蛋白分子及其编码序列和用途
JP2001518794A (ja) ヒトgtp結合タンパク質
US20040143111A1 (en) Novel apoptosis-associated protein
JP2001517942A (ja) ヒト腫瘍抑制遺伝子
CA2305693A1 (en) Mammalian mesoderm induction early response (m-mier) gene family
JP2002503103A (ja) 新規のヒトdp1相同体
MXPA99000406A (en) Brca1 compositions and methods for the diagnosis and treatment of breast cancer